Education
About Us
Working with TipRanks
Follow Us
Grifols, SA (GB:0RDU)
LSE:0RDU
0RDU Stock Chart & Stats
€10.52
-€0.09(-0.95%)
At close: 4:00 PM EST
€10.52
-€0.09(-0.95%)
Day’s Range― - ―
52-Week Range€7.36 - €13.70
Previous CloseN/A
Volume20.05K
Average Volume (3M)125.85K
Market Cap
€6.33B
Enterprise Value€15.90B
Total Cash (Recent Filing)€825.49M
Total Debt (Recent Filing)€9.64B
Price to Earnings (P/E)18.3
Beta1.03
Next Earnings
Apr 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.14
Shares Outstanding426,129,800
10 Day Avg. Volume28,144
30 Day Avg. Volume125,850
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.40
Price to Sales (P/S)0.98
P/FCF Ratio9.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.50Price Target Upside28.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.9
Revenue Forecast (FY)€7.84B
Bulls Say, Bears Say
Bulls Say
Revenue & Margin RecoverySustained mid-to-high single-digit revenue growth and a recovery in EBIT margin to ~16.6% indicate resilient end-market demand and improving operating leverage. That supports durable cash flow generation and a more stable earnings base over the next 2–6 months as execution continues.
Positive Free Cash FlowConsistently positive free cash flow and material operating cash generation versus the 2022–2023 trough strengthen internal funding capacity. Improved FCF supports deleveraging, reinvestment in manufacturing and reagents, and reduces reliance on external financing over a multi-quarter horizon.
Clear Deleveraging Plan & Ratings MomentumManagement’s explicit multi-year deleveraging targets and public guidance on FCF/EBITDA create a credible financial roadmap. Combined with recent credit-rating upgrades and positive outlooks, this structural plan increases odds of sustained funding access and lower refinancing costs.
Bears Say
High LeverageVery high absolute debt and a debt-heavy capital structure constrain financial flexibility. Elevated leverage increases sensitivity to cash-flow shocks, limits room for transformational M&A or large capital projects, and means deleveraging will be a structural priority over many quarters.
Limited Debt Coverage By Cash FlowOperating cash flow remains modest relative to total debt, and recent negative FCF growth signals that capacity to pay down principal is constrained. This implies that deleveraging may be gradual and refinancing risk persists until sustained FCF growth is re-established.
Margins & Earnings VolatilityAlthough margins have rebounded, they remain materially below prior peaks and earnings have been uneven. Persistent margin gap and volatility suggest exposure to pricing, mix or cost pressures that could limit sustainable profitability and slower margin expansion ahead.
Grifols News
0RDU FAQ
What was Grifols, SA’s price range in the past 12 months?
Grifols, SA lowest share price was €7.36 and its highest was €13.70 in the past 12 months.
What is Grifols, SA’s market cap?
Grifols, SA’s market cap is €6.33B.
When is Grifols, SA’s upcoming earnings report date?
Grifols, SA’s upcoming earnings report date is Apr 30, 2026 which is in 55 days.
How were Grifols, SA’s earnings last quarter?
Grifols, SA released its earnings results on Feb 26, 2026. The company reported €0.144 earnings per share for the quarter, missing the consensus estimate of €0.255 by -€0.111.
Is Grifols, SA overvalued?
According to Wall Street analysts Grifols, SA’s price is currently Undervalued.
Does Grifols, SA pay dividends?
Grifols, SA does not currently pay dividends.
What is Grifols, SA’s EPS estimate?
Grifols, SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Grifols, SA have?
Grifols, SA has 426,129,800 shares outstanding.
What happened to Grifols, SA’s price movement after its last earnings report?
Grifols, SA reported an EPS of €0.144 in its last earnings report, missing expectations of €0.255. Following the earnings report the stock price went up 0.182%.
Which hedge fund is a major shareholder of Grifols, SA?
Currently, no hedge funds are holding shares in GB:0RDU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Grifols Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€13.50 (28.33% Upside)
€13.50 (28.33% Upside)
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.39%
12-Months-Change
Fundamentals
Return on Equity
5.53%
Trailing 12-Months
Asset Growth
-11.32%
Trailing 12-Months
Company Description
Grifols, SA
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solutions to treat patients with chronic, rare, prevalent, and life-threatening diseases. It offers immunoglobulins, alpha-1 antitrypsin, albumin, clotting factors, and hyperimmune globulins. The Hospital division offers non-biological pharmaceutical products and medical supplies clinical nutrition, intravenous therapy, and medical devices. The Diagnostic division researches, develops, produces, and commercializes diagnostic products that span the healthcare continuum from prevention, screening, diagnosis, and prognosis to disease and treatment monitoring to serve professionals. The Bio Supplies division provides biological materials for life-science research, clinical trials, and for manufacturing pharmaceutical and diagnostic products. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves public and private customers; and wholesalers, distributors, group purchasing organizations, blood banks, hospitals and care institutions, and national health systems. Grifols, S.A. has a technology collaboration agreement with Mondragon. The company was founded in 1940 and is headquartered in Barcelona, Spain.
0RDU Stock 12 Month Forecast
Average Price Target
€13.50
▲(28.33% Upside)
Technical Analysis
Almirall
―
Faes Farma
―
LABORATORIO REIG JOFRE
―
Laboratorios Farmaceuticos Rovi
―
Pharma Mar SA
―
Options Prices
Currently, No data available
---